Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Inotiv, Inc is a diagnostics & research business based in the US. Inotiv shares (NOTV) are listed on the NASDAQ and all prices are listed in US Dollars. Inotiv employs 397 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$4.47 - $31.98|
|50-day moving average||$28.33|
|200-day moving average||$21.65|
|Wall St. target price||$31.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Inotiv stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inotiv's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Inotiv's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 million.
The EBITDA is a measure of a Inotiv's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$68.2 million|
|Gross profit TTM||$18.2 million|
|Return on assets TTM||-1.14%|
|Return on equity TTM||-44.23%|
|Market capitalisation||$443.6 million|
TTM: trailing 12 months
There are currently 368,838 Inotiv shares held short by investors – that's known as Inotiv's "short interest". This figure is 6% down from 392,465 last month.
There are a few different ways that this level of interest in shorting Inotiv shares can be evaluated.
Inotiv's "short interest ratio" (SIR) is the quantity of Inotiv shares currently shorted divided by the average quantity of Inotiv shares traded daily (recently around 186281.81818182). Inotiv's SIR currently stands at 1.98. In other words for every 100,000 Inotiv shares traded daily on the market, roughly 1980 shares are currently held short.
However Inotiv's short interest can also be evaluated against the total number of Inotiv shares, or, against the total number of tradable Inotiv shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inotiv's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Inotiv shares in existence, roughly 20 shares are currently held short) or 0.0332% of the tradable shares (for every 100,000 tradable Inotiv shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inotiv.
Find out more about how you can short Inotiv stock.
We're not expecting Inotiv to pay a dividend over the next 12 months.
Over the last 12 months, Inotiv's shares have ranged in value from as little as $4.47 up to $31.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inotiv's is 2.1387. This would suggest that Inotiv's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.